Stefano Ferrari

Active 1985–2025

249
Papers
32,873
Citations
103
h-index
221
i10-index

Citations

Citations per year for Stefano Ferrari1985: 1 citations1986: 12 citations1987: 10 citations1988: 5 citations1989: 6 citations1990: 13 citations1991: 18 citations1992: 25 citations1993: 10 citations1994: 35 citations1995: 39 citations1996: 35 citations1997: 43 citations1998: 41 citations1999: 63 citations2000: 85 citations2001: 123 citations2002: 152 citations2003: 179 citations2004: 157 citations2005: 184 citations2006: 179 citations2007: 170 citations2008: 189 citations2009: 248 citations2010: 234 citations2011: 275 citations2012: 223 citations2013: 284 citations2014: 301 citations2015: 263 citations2016: 314 citations2017: 287 citations2018: 297 citations2019: 988 citations2020: 1,129 citations2021: 1,031 citations2022: 773 citations2023: 504 citations2024: 815 citations2025: 316 citations2026: 8 citations

Citation sources

Countries

World map of the countries and regions citing this authorUnited States: 2,696 citing papers, 22.1% of this breakdownChina: 1,207 citing papers, 9.9% of this breakdownItaly: 1,021 citing papers, 8.3% of this breakdownUnited Kingdom: 893 citing papers, 7.3% of this breakdownGermany: 693 citing papers, 5.7% of this breakdownFrance: 635 citing papers, 5.2% of this breakdownJapan: 411 citing papers, 3.4% of this breakdownSwitzerland: 372 citing papers, 3% of this breakdownCanada: 360 citing papers, 2.9% of this breakdownNetherlands: 360 citing papers, 2.9% of this breakdownSpain: 326 citing papers, 2.7% of this breakdownIndia: 277 citing papers, 2.3% of this breakdown
0%22.1%Other 24.3%

Fields

  • Medicine55.5%
  • Biochemistry, Genetics and Molecular Biology29.8%
  • Engineering3.3%
  • Computer Science3.1%
  • Neuroscience1.6%
  • Immunology and Microbiology1.5%
  • Other5.2%

Topics

  • Sarcoma Diagnosis and Treatment7.4%
  • Bone Tumor Diagnosis and Treatments2.9%
  • Mesenchymal stem cell research2.9%
  • Metal complexes synthesis and properties1.4%
  • Endometriosis Research and Treatment1.3%
  • Tissue Engineering and Regenerative Medicine1.3%
  • Other82.8%

Coauthors

All papers

Open in search
  1. Soft tissue and visceral sarcomas: ESMO–EURACAN Clinical Practice Guidelines for diagnosis, treatment and follow-up

    Authors: , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , Rolf D. Issels, Heikki Joensuu, Robin L. Jones, Ian Judson, Paul C. Jutte, Suzanne E. J. Kaal, Bernd Kasper, Kateřina Kopečková, Dagmar Adámková Krákorová, Axel Le Cesne, Iwona Ługowska, Ofer Merimsky, Michael Montemurro, Maria A. Pantaleo, Raimondo Piana, Piero Picci, Sophie Piperno‐Neumann, A.L. Pousa, Peter Reichardt, Martin Robinson, Piotr Rutkowski, Akmal Safwat, Patrick Schöffski, Stefan Sleijfer, Silvia Stacchiotti, Kirsten Sundby Hall, Mojca Unk, Frits van Coevorden, W. Van der Graaf, Jeremy Whelan, Eva Wardelmann, Olga Zaikova, Jean‐Yves Blay - Annals of Oncology 2018 cited by 1,621

  2. Macrophages Are Alternatively Activated in Patients with Endometriosis and Required for Growth and Vascularization of Lesions in a Mouse Model of Disease

    Authors: , , , , , , , , , , , , - American Journal Of Pathology 2009 cited by 446

  3. Retinitis Pigmentosa: Genes and Disease Mechanisms

    Authors: , , , , , - Current Genomics 2011 cited by 656

  4. Self-Renewing Osteoprogenitors in Bone Marrow Sinusoids Can Organize a Hematopoietic Microenvironment

    Authors: , , , , , , , , , , - Cell 2007 cited by 2,206

  5. Bone sarcomas: ESMO–PaedCan–EURACAN Clinical Practice Guidelines for diagnosis, treatment and follow-up

    Authors: , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , Giovanni Grignani, Alessandro Gronchi, Rick L. Haas, A. Bassim Hassan, Stefanie Hecker‐Nolting, Peter Hohenberger, Rolf D. Issels, Heikki Joensuu, Robin L. Jones, Ian Judson, Paul C. Jutte, Suzanne E. J. Kaal, Leo Kager, Bernd Kasper, Kateřina Kopečková, Dagmar Adámková Krákorová, Ruth Ladenstein, Axel Le Cesne, Iwona Ługowska, Ofer Merimsky, Michael Montemurro, Bruce Morland, Maria A. Pantaleo, Raimondo Piana, Piero Picci, Sophie Piperno‐Neumann, A.L. Pousa, Peter Reichardt, Martin Robinson, Piotr Rutkowski, Akmal Safwat, Patrick Schöffski, Stefan Sleijfer, Silvia Stacchiotti, Sandra J. Strauss, Kirsten Sundby Hall, Mojca Unk, Frits van Coevorden, Winette T.A. van der Graaf, Jeremy Whelan, Eva Wardelmann, Olga Zaikova, Jean‐Yves Blay - Annals of Oncology 2018 cited by 641

  6. Combination of Ru(ii) complexes and light: new frontiers in cancer therapy

    Authors: , , , - Chemical Science 2015 cited by 554

  7. A Survey of Unsupervised Generative Models for Exploratory Data Analysis and Representation Learning

    Authors: , , , , - ACM Computing Surveys, ACM Comput. Surv. 2021 cited by 104

  8. Ewing Sarcoma: Current Management and Future Approaches Through Collaboration

    Authors: , , , , , , , , , , , , , , , , , , , , , , , , , , - Journal of Clinical Oncology 2015 cited by 733

  9. Anatomy and physiology of the human eye: effects of mucopolysaccharidoses disease on structure and function – a review

    Authors: , , , , , - Clinical and Experimental Ophthalmology 2010 cited by 208

  10. A phase II trial of sorafenib in relapsed and unresectable high-grade osteosarcoma after failure of standard multimodal therapy: an Italian Sarcoma Group study

    Authors: , , , , , , , , , , , - Annals of Oncology 2011 cited by 356

  11. Bone Marrow Mesenchymal Stromal/Stem Cell-Derived Extracellular Vesicles Promote Corneal Wound Repair by Regulating Inflammation and Angiogenesis

    Authors: , , , , , , , , , , , , , - Cells 2022 cited by 50

  12. Sorafenib and everolimus for patients with unresectable high-grade osteosarcoma progressing after standard treatment: a non-randomised phase 2 clinical trial

    Authors: , , , , , , , , , , , , , , , , , - The Lancet Oncology 2014 cited by 335

  13. Histotype-tailored neoadjuvant chemotherapy versus standard chemotherapy in patients with high-risk soft-tissue sarcomas (ISG-STS 1001): an international, open-label, randomised, controlled, phase 3, multicentre trial

    Authors: , , , , , , , , , , , , , , , , , , , , , , , , , , - The Lancet Oncology 2017 cited by 489

  14. Correction of junctional epidermolysis bullosa by transplantation of genetically modified epidermal stem cells

    Authors: , , , , , , , , , , , , , , - Nature Medicine 2006 cited by 663

  15. High‐dose methotrexate‐induced nephrotoxicity in patients with osteosarcoma

    Authors: , , , , , , , , - Cancer 2004 cited by 322

  16. Approaches for corneal endothelium regenerative medicine

    Authors: , , , , , , , , , , - Progress in Retinal and Eye Research 2021 cited by 102

  17. Benefits and Adverse Events in Younger Versus Older Patients Receiving Neoadjuvant Chemotherapy for Osteosarcoma: Findings From a Meta-Analysis

    Authors: , , , , , , , , , , , , , , , , - Journal of Clinical Oncology 2013 cited by 186

  18. Denosumab treatment of inoperable or locally advanced giant cell tumor of bone – Multicenter analysis outside clinical trial

    Authors: , , , , , , , , , , , , , , , , - European Journal of Surgical Oncology 2018 cited by 112

  19. Concomitant Autoimmunity in Endometriosis Impairs Endometrium–Embryo Crosstalk at the Implantation Site: A Multicenter Case-Control Study

    Authors: , , , , , , , , - Journal of Clinical Medicine 2023 cited by 28

  20. High-risk soft tissue sarcomas treated with perioperative chemotherapy: Improving prognostic classification in a randomised clinical trial

    Authors: , , , , , , , , , , , , , , , , , , , , , - European Journal of Cancer 2018 cited by 85

  21. Pathophysiology of aniridia-associated keratopathy: Developmental aspects and unanswered questions

    Authors: , , , , , , , , , , , , - The Ocular Surface 2021 cited by 77

  22. Safety and efficacy of denosumab for adults and skeletally mature adolescents with giant cell tumour of bone: interim analysis of an open-label, parallel-group, phase 2 study

    Authors: , , , , , , , , , , , , , , , - The Lancet Oncology 2013 cited by 583

  23. Molecular and Cellular Characterization of the Biological Effects of Ruthenium(II) Complexes Incorporating 2-Pyridyl-2-pyrimidine-4-carboxylic Acid

    Authors: , , , , , , , , - Journal of the American Chemical Society 2012 cited by 298

  24. Dual mode of cell death upon the photo-irradiation of a RuIIpolypyridyl complex in interphase or mitosis

    Authors: , , , , , , - Chemical Science 2016 cited by 95